FATE

FATE is a pre-commercial, clinical-stage cell-therapy company whose entire value rests on an iPSC-derived CAR T/NK pipeline for which the provided data contains zero clinical readouts. Management states it plainly: the company has "never been profitable and have incurred net losses in each year since inception," and does "not expect to generate any meaningful revenues from product sales, royalties, or sales milestones unless and until we successfully" commercialize a candidate. The FY2025 P/S of 51x is meaningless because the $6.65M of "revenue" is collaboration/grant income (largely the Ono agreement), not product sales — and it is evaporating, down 51% YoY and down from $96.3M in FY2022 to $6.65M in FY2025. That collapse signals the collaboration engine winding down, not a business scaling.

The balance sheet is the one point of comfort but does not make this investable. Stockholders' equity is $207M and current assets are $209M against just $36.1M of current liabilities, with the stale FY2018 debt lines implying no material leverage today. But operating cash flow was -$106M in FY2025 and R&D was still $108M, so the liquid pile funds only roughly two years of burn before the company must return to the market — consistent with its stated history of funding "primarily through the public and private sale of common stock and warrants." Share count rose only 1.5% this year, but a -$1.53B accumulated deficit is the record of how much capital this model consumes.